Beta Drugs shareholders and shareholding pattern
Last close ₹1,894.60down ₹76.40 (3.88%)
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,971.00.
52-week range of traded prices to 23 Oct 2026
₹990.10Low, 25 Feb 2026₹2,807.90High, 12 Aug 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹2,107 Cr1,305th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 22 Oct 2026
- 39.0
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 22 Oct 2026
- 4.8
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 22 Oct 2026
- 16.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 22 Oct 2026
- 14.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. The filing of 22 Oct 2026
- 0.10
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,55,58635.7% delivered
Who owns Beta Drugs, filing by filing
Per cent of the company's shares. Every filing on record, from Sep 2021; the latest is the filing for Sep 2026.
Sep 2026 filing
- Promoters58.91%
- Foreign institutions1.37%
- Indian institutions6.45%
- Individuals and others33.27%
Shareholding pattern, per cent, from Sep 2022
- Promoters
- Foreign institutions
- Indian institutions
- Individuals and others
| Per cent | Sep 2021Filed 11 Oct | Dec 2021Filed 6 Jan | Mar 2022Filed 8 Apr | Jun 2022Filed 16 Jul | Sep 2022Filed 15 Oct | Dec 2022Filed 9 Jan | Mar 2023Filed 10 Apr | Jun 2023Filed 11 Jul | Sep 2023Filed 9 Oct | Dec 2023Filed 8 Jan | Mar 2024Filed 15 Apr | Jun 2024Filed 19 Jul | Sep 2024Filed 12 Oct | Dec 2024Filed 14 Jan | Mar 2025Filed 8 Apr | Jun 2025Filed 9 Jul | Sep 2025Filed 13 Oct | Dec 2025Filed 13 Jan | Mar 2026Filed 6 Apr | Jun 2026Filed 17 Jul | Sep 2026Filed 14 Oct |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 66.68% | 66.71% | 66.71% | 66.71% | 66.71% | 66.71% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 64.90% | 64.63% | 59.10% | 58.91% | |
| Indian promoters | 66.68% | 66.71% | 66.71% | 66.71% | 66.71% | 66.71% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 66.73% | 64.90% | 64.63% | 59.10% | 58.91% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. | 33.31% | 33.30% | 33.29% | 33.29% | 33.29% | 33.29% | 33.27% | 33.26% | 33.27% | 33.26% | 33.25% | 33.27% | 33.27% | 33.27% | 33.27% | 33.27% | 33.27% | 35.10% | 35.37% | 40.90% | 41.09% |
| Shares in issue | 96,13,790 | 96,13,790 | 96,13,790 | 96,13,790 | 96,13,790 | 96,13,790 | 96,13,790 | 96,13,790 | 96,13,790 | 96,13,790 | 96,13,790 | 96,13,790 | 96,13,790 | 96,13,860 | 1,00,94,553 | 1,00,94,553 | 1,00,94,553 | 1,00,94,553 | 1,01,36,890 | 1,10,85,872 | 1,11,21,255 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. | 2,45,713 | 2,45,713 | 2,45,713 | 2,45,713 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14,070 | 14,773 | 73 | – | – | – | 2,83,668 | 2,83,668 |
| Promoters' shares locked in | 2,45,713 | 2,45,713 | 2,45,713 | 2,45,713 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – | – | – | – |
Filings before Sep 2022 are on an older form, which did not split institutions into foreign and Indian and grouped some holders differently, so those columns show only the lines both forms state alike. A dash is a line the filing did not state. “Under 0.01%” is a holding of shares too small to show at two decimals.
Beta Drugs promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing for Sep 2026; the largest is NEERAJ BATRA, 58.21%.Promoter buying and selling
| Holder | ||
|---|---|---|
| NEERAJ BATRAIndividuals and Hindu undivided families | 58.21% | 64,73,631 |
| RAHUL BATRAIndividuals and Hindu undivided families | 0.37% | 41,632 |
| VARUN BATRAIndividuals and Hindu undivided families | 0.31% | 34,891 |
| HEENA BATRAIndividuals and Hindu undivided families | 0.01% | 619 |
| ADITI BATRAIndividuals and Hindu undivided families | 0.01% | 619 |
No promoter shares are reported as pledged.
Largest public holders of Beta Drugs, filing by filing
Per cent, on the same shares as the split above.
| Holder | Sep 2021Filed 11 Oct | Dec 2021Filed 6 Jan | Mar 2022Filed 8 Apr | Jun 2022Filed 16 Jul | Sep 2022Filed 15 Oct | Dec 2022Filed 9 Jan | Mar 2023Filed 10 Apr | Jun 2023Filed 11 Jul | Sep 2023Filed 9 Oct | Dec 2023Filed 8 Jan | Mar 2024Filed 15 Apr | Jun 2024Filed 19 Jul | Sep 2024Filed 12 Oct | Dec 2024Filed 14 Jan | Mar 2025Filed 8 Apr | Jun 2025Filed 9 Jul | Sep 2025Filed 13 Oct | Dec 2025Filed 13 Jan | Mar 2026Filed 6 Apr | Jun 2026Filed 17 Jul | Sep 2026Filed 14 Oct |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SURYAVANSHI COMMOTRADE PRIVATE LIMITEDCompanies | 6.71% | 6.71% | 6.71% | 6.71% | 6.71% | 6.71% | 6.71% | 6.74% | 6.74% | 6.74% | 6.74% | 6.74% | 6.74% | 6.74% | 6.74% | 6.74% | 6.74% | 6.74% | 6.71% | 6.13% | 6.11% |
| ASHISH KACHOLIAResident individuals, over ₹2 lakh at face value | 5.62% | 5.72% | 5.72% | 5.72% | 5.72% | 5.72% | 5.78% | 5.78% | 5.78% | 5.78% | 5.78% | 5.78% | 5.78% | 5.78% | 5.78% | 5.78% | 5.78% | 5.78% | 5.76% | 4.91% | 4.43% |
| HEALTHQUAD TRUST IIAlternative investment funds | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 4.09% | 4.28% |
| INTI CAPITAL VCC - INTI CAPITAL IForeign companies | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.91% | 2.00% |
| AIRAVAT CAPITAL TRUST - AIRAVAT CAPITAL TRUST IIAlternative investment funds | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.54% | 1.68% | 1.60% | 1.59% |
| BSAS INFOTECH LIMITEDCompanies | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | 1.27% | 1.31% | 1.20% | 1.19% |
| ANJALI AJIT DEVALResident individuals, over ₹2 lakh at face value | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.13% | 1.13% |
| ONKAR SINGHResident individuals, over ₹2 lakh at face value | 1.05% | 1.05% | 1.05% | 1.05% | 1.05% | 1.05% | 1.05% | 1.05% | 1.05% | 1.05% | 1.05% | 1.05% | 1.05% | 1.05% | 1.06% | 1.06% | 1.06% | 1.06% | 1.06% | – | 1.01% |
| Surendra Kumar JainResident individuals, over ₹2 lakh at face value | 1.04% | 1.04% | 1.04% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.02% | – | – |
| ANKUSH KEDIAResident individuals, over ₹2 lakh at face value | 1.11% | 1.06% | 1.06% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. A dash is a filing that did not name the holder, which includes holding under one per cent.